- Home
- CUE vs SST Comparison
CUE vs SST Comparison
Compare CUE & SST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CUE | SST |
|---|---|---|
| Founded | 2014 | 2013 |
| Country | United States | United States |
| Employees | N/A | 300 |
| Industry | Biotechnology: Pharmaceutical Preparations | Diversified Commercial Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.1M | 27.4M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | CUE | SST |
|---|---|---|
| Price | $0.31 | $2.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $3.00 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 316.8K | 7.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 35.14 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,287,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $25.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 69.16 | N/A |
| 52 Week Low | $0.23 | $0.29 |
| 52 Week High | $1.12 | $11.30 |
Technical Indicators
Market Signals| Indicator | CUE | SST |
|---|---|---|
| Relative Strength Index (RSI) | 47.64 | 33.87 |
| Support Level | $0.29 | $0.34 |
| Resistance Level | $0.36 | $3.57 |
| Average True Range (ATR) | 0.02 | 0.26 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 73.35 | 17.11 |
Price Performance
Historical ComparisonAbout CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
About SST System1 Inc.
System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It serves customers in the areas of health and wellness, automotive, finance, travel, and entertainment. The company's segment includes Owned and Operated Advertising (O&O); and Partner Network. It generates maximum revenue from the Owned and Operated Advertising (O&O) segment. Geographically, it operates in United States and Other countries.